Pricing Log in Create free account
Saturday 7 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

20.11 0.66 +3.39%
Market cap
$6.8B
P/E
38.2×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revenue by segment Fiscal 2025

  • Affordable Medicines
  • AvKARE
  • Specialty

Every year since 2016 →

Insider Decisions last twelve months

Sold, $m 7.67
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — 1 — — 3 — — —
Insider Ownership 53.34%

Capital & Financial Ratios $m

Size
Market Cap 6,770.00
Revenue ttm 3,195.72
Net income ttm 209.49
Free cash flow ttm (60.46)
Net debt Q 3,013.45
Valuation
P/E 38.18 (above 35: high)
Forward P/E 44.20 (above 35: high)
Price / sales 2.11
Forward P/S Powerpack
Price / FCF 0.00
Price / book 61.68 (above 6: high)
Financial health
Current ratio Q 1.87 (at or above 1.5: strong)
Debt / equity Q 6.00 (above 2: weak)
Interest coverage Q 1.62
Growth
Revenue growth Q +9.96% (above 0%: growing)
Operating income growth Q +35.64% (above 0%: growing)
EPS, this year +25.76% (at or above 15%: strong)
EPS, next year A +18.04% (at or above 15%: strong)
Revenue, next year A +4.74%
EPS, past 5 yrs −18.45% (below 0%: weak)
EPS, next 5 yrs A +20.63% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.1×, against a ten-year median of 1.7×; over the ten years it ranged from 1.2× in 2023 to 4.4× in 2018.
P/S against its own 10 years 97.76%
10-year low 10-year high
P/B against its own 10 years 95.05%
10-year low 10-year high
EV/Sales against its own 10 years 93.83%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 99 118 311 172
Receivables 615 776 896 1,019
Inventory 581 612 606 708
Other — — — —
1,378 1,588 1,911 2,095
2023 2024 2025 Q'26
Payables 535 735 761 789
ST’ Debt 213 324 7 204
Other 77 32 43 87
847 1,130 882 1,120

Compound Annual Growth %

10y 5y 3y
Sales 13.37% 8.66% 10.92%
Cash Flow 13.91% (2.15%) 73.50%
Earnings 2.31% (4.57%) 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.24 Actual 0.26

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.18 0.21 Beat by 0.03
Q1 FY26 0.17 0.27 Beat by 0.10
Q2 FY26 0.24 0.30 Beat by 0.06
Q3 FY26 0.24 0.26 Beat by 0.02
Q4 FY26 0.24 — Reports 26 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.19 0.18 0.04 — —
’25 0.04 0.07 0.01 0.11 0.22
’24 (0.30) 0.02 0.00 (0.10) (0.38)
’23 (0.05) 0.08 0.06 (0.56) (0.48)
’22 (0.01) (0.80) (0.02) (0.03) (0.86)
’21 0.04 0.10 (0.04) (0.04) 0.07
’20 0.78 (0.08) (0.15) (0.02) 0.61
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 723 796 863 — —
’25 695 725 785 814 3,019
’24 659 702 702 731 2,794
’23 558 599 620 617 2,394
’22 498 559 546 610 2,212
’21 493 535 529 537 2,094
’20 499 465 519 510 1,993
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (27) (21) 98 — —
’25 7 84 118 130 340
’24 (4) 40 142 118 295
’23 140 (11) 81 136 346
’22 120 (126) 94 (23) 65
’21 148 (52) 82 63 242
’20 49 179 45 106 379
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (48) (144) 47 — —
’25 (10) 57 96 85 228
’24 (24) 28 121 95 220
’23 128 (24) 68 104 276
’22 108 (143) (39) 49 (25)
’21 135 (61) (3) 123 194
’20 41 (83) 30 326 313
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 13.8% a year for ten years. It grew 17.8% a year over the last ten.

Implied
13.8%
10 years, reported
17.8%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1,018 1,034 1,663 1,626 1,993 2,094 2,212 2,394 2,794 3,019 3,196 +12.8% 3,162 3,458 3,814 +8.1%
Gross margin, % 58.68 50.90 43.08 21.70 31.54 36.73 35.47 34.28 36.52 36.88 40.24 (21.8) pt
EBT 215 171 (203) (220) (36) 31 (248) (40) (55) 139 221 (4.7%)
EBT margin, % 21.10 16.57 (12.19) (13.54) (1.80) 1.50 (11.22) (1.68) (1.97) 4.61 6.93 (16.5) pt
Net income 209 169 (201) (604) 69 20 (255) (49) (74) 128 209 (5.3%)
Per share, $
Per share, $ Revenue 14.34 13.97 13.07 12.31 13.51 14.06 14.66 13.59 9.04 9.63 9.52 (4.3%)
Earnings — (6.53) (0.16) (2.74) 0.62 0.07 (0.86) (0.48) (0.38) 0.23 0.53 n/m
Cash flow 1.62 3.16 1.97 0.01 2.57 1.62 0.43 1.96 0.96 1.09 0.54 (4.4%)
Capex (1.75) (1.54) (0.56) (0.74) (0.45) (0.32) (0.60) (0.39) (0.24) (0.36) (0.72) (16.2%)
Free cash flow (0.13) 1.62 1.40 (0.72) 2.12 1.30 (0.17) 1.57 0.71 0.73 (0.18) n/m
Book value 8.79 (5.08) 7.04 2.63 2.34 2.46 1.22 0.11 (0.35) (0.23) 1.58 n/m
Shares, m 71 74 127 132 147 149 151 176 309 313 321 +17.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 8.61 69.22 0.00 0.00 0.00 54.78 38.18 13.3
P/S 0.96 0.96 1.04 0.39 0.34 0.34 0.14 0.44 0.88 1.31 2.11 0.7
P/B 18.03 18.03 1.92 1.84 1.95 1.94 1.73 52.64 0.00 0.00 61.68 9.8
EV/Sales 1.56 1.56 2.52 1.95 1.61 1.53 1.36 1.50 1.74 2.06 3.06 1.7
EV/FCF 18.63 18.63 23.50 (33.18) 10.24 7.21 63.75 13.01 22.13 27.27 (161.50) 17.1
Cash, $m
Cash, $m Operating cash flow 115 234 250 2 379 242 65 346 295 340 181 +12.8%
Capex (125) (114) (72) (97) (66) (48) (91) (69) (75) (112) (241) (1.2%)
Free cash flow (10) 120 178 (96) 313 194 (25) 276 220 228 (60) n/m
Balance, $m
Balance, $m Working capital 310 475 733 660 875 843 659 531 458 1,030 975 +14.3%
Net debt 651 1,407 2,472 2,539 2,529 2,492 2,686 2,541 2,424 2,316 3,013 +15.1%
Shareholders’ equity 624 (376) 896 347 345 367 184 20 (110) (71) 531 n/m
Returns, %
Returns, % ROA 0.00 0.00 (0.73) (9.03) 2.37 0.27 (3.36) (2.31) (3.35) 2.01 3.01 +2.0 pt
ROIC 13.96 14.86 (0.36) (5.39) 1.98 3.34 (2.07) 4.99 6.73 10.97 8.45 (3.0) pt
ROE 0.00 0.00 (8.03) (58.23) 26.33 2.98 (47.19) (82.35) 261.19 (79.69) (53,107.17) (79.7) pt
People
People Employees 1,495 1,257 6,000 5,500 6,000 7,000 7,600 7,700 8,100 8,500 — +21.3%
Revenue/emp, $m 0.68 0.82 0.28 0.30 0.33 0.30 0.29 0.31 0.34 0.36 — (7.0%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Business profile

Updated

Amneal Pharmaceuticals develops, manufactures, markets and distributes medicines. Its business spans generic drugs, biosimilars, branded medicines and pharmaceutical distribution. It operates principally in the United States, India and Ireland, and is headquartered in Bridgewater Township. Chirag Patel and Chintu Patel are co-chief executive officers.

The Affordable Medicines business sells generics, injectable medicines and biosimilars. Generics contain the same active ingredient as their branded counterparts and are generally sold at lower prices. Biosimilars are versions of biological medicines, which are made using biological processes. Amneal’s products reach pharmacies, hospitals and other institutions through wholesalers, distributors and direct sales.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by segment, and margins
Affordable Medicines 1,746 57.82%
AvKARE 745 24.67%
Specialty 529 17.51%
Gross margin 36.88%
Operating margin 13.05%
Pre-tax margin 4.61%

Revenue by segment since 2016

AMNEAL PHARMACEUTICALS, INC. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RDY Dr. Reddy's Laboratories Ltd $12.1B 45.4× 30.7× −10.09% (below 0%: shrinking) −36.84% (below 0%: shrinking) −70.49% (below 0%: shrinking) 52.13% 14.63% Compare
ELAN Elanco Animal Health Incorporated $11.8B — (loss-making) 161× +11.26% (above 0%: growing) n/m +22.83% (above 0%: growing) 56.92% 0.00% Compare
ALKS Alkermes plc $7.5B — (loss-making) — (loss-making) +21.80% (above 0%: growing) −80.60% (below 0%: shrinking) +6.78% (above 0%: growing) 80.38% 7.50% Compare
KNSA Kiniksa Pharmaceuticals International, plc $6.9B 65.9× 67.8× +58.12% (above 0%: growing) +142.20% (above 0%: growing) +43.51% (above 0%: growing) 90.29% 18.97% Compare
AMRX AMNEAL PHARMACEUTICALS, INC. $6.8B 38.2× 44.2× +9.96% (above 0%: growing) +267.00% (above 0%: growing) −50.92% (below 0%: shrinking) 38.73% 11.06%
LNTH Lantheus Holdings, Inc. $6.6B 24.3× 21.3× +1.54% (above 0%: growing) −16.44% (below 0%: shrinking) +7.71% (above 0%: growing) 62.43% 8.26% Compare
HIMS Hims & Hers Health, Inc. $5.6B — (loss-making) — (loss-making) +38.25% (above 0%: growing) n/m +5.09% (above 0%: growing) 63.83% (12.90%) Compare
SUPN Indivior Pharmaceuticals Inc. $5.6B 7.0× 9.5× +13.38% (above 0%: growing) +241.47% (above 0%: growing) +240.68% (above 0%: growing) 85.67% 50.84% Compare
LQDA Liquidia Corporation $4.0B 28.4× 22.1× +1,842.73% (above 0%: growing) n/m +270.23% (above 0%: growing) 93.27% 49.81% Compare
Median of peers $6.8B 28.4× 26.4× +17.59% −16.44% +15.27% 72.11% 11.45%

All 84 Drug Manufacturers Specialty & Generic stocks →

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 52.68%
Held by the ten largest 31.99%
Holder Shares Stake Change
BlackRock 26.56m 8.32% +2.04m
Vanguard 21.26m 6.66% +941.80k
TPG GP A, LLC 12.33m 3.86% 0.00
Rubric Capital Management LP 10.17m 3.18% −868.93k
State Street 7.36m 2.30% +562.28k
Dimensional Fund Advisors 5.79m 1.81% +103.68k
Geode Capital Management 5.14m 1.61% +593.40k
Assenagon Asset Management S.A. 4.89m 1.53% +1.82m
Nantahala Capital Management, LLC 4.54m 1.42% +1.69m
Morgan Stanley 4.11m 1.29% −527.16k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Latest News

4 Nov

Impact 4 · · Zacks
Impact 3 · · Simply Wall St.

3 Nov

Impact 4 · · Moby
Impact 3 · · MarketBeat transcript
Impact 3 · · Zacks
Impact 3 · · StockStory
Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · Simply Wall St.

28 Oct

Impact 3 · · Zacks

27 Oct

Impact 3 · · Zacks
Impact 3 · · Zacks
Impact 3 · · Zacks

26 Oct

Impact 3 · · Zacks

24 Oct

Impact 4 · · Simply Wall St.

3 Oct

Impact 3 · · Simply Wall St.

21 Sep

Impact 4 · · StockStory

18 Sep

Impact 4 ·

4 Sep

Impact 4 ·

12 Aug

Impact 3 ·

1 Aug

Impact 3 ·

31 Jul

Impact 3 ·

30 Jul

Impact 4 ·
Impact 4 ·
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat
Impact 3 ·

29 Jul

Impact 4 ·

17 Jul

Impact 3 ·

15 Jul

Impact 3 ·

AMRX metrics, ten years each

stockrow.com/AMRX · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com